step · intermediate · partly written
Target and gene module
One step of the screening cascade walk-through, from disease to clinic.
What is done
Fine-mapping narrows a locus to candidate variants; colocalisation with expression data and locus-to-gene models nominate a gene; rare-variant burden tests and Mendelian randomisation add gene-level evidence. A gene module is a statistical set of genes, for which no single sourced definition was found. 12
Reported, not yet replicated
Proves
That a gene is a candidate, and, for Mendelian evidence, that it has a better track record: relative clinical success is 2.6 overall and 3.7 for Mendelian evidence in one analysis. 3
Reported, not yet replicated
Cannot prove
That the gene call is right or that the drug direction is known. The locus-to-gene model got 0.73 precision at best, with no clear gain over the nearest gene in one benchmark read at abstract level; success estimates are retrospective; no trial that failed because of a wrong gene call was found in the chain's search, which is a web search and not a review of terminated trials. 13
Contested
Assays
- a record that is not published here
- Genome-wide association study (GWAS)
ML role
A gradient-boosted model over distance, QTL colocalisation, variant effect and chromatin scores genes at each locus; it does not establish causation or the direction of a drug effect. 1
Reported, not yet replicated
Reports
- a record that is not published here
Modality notes
Common disease: mostly inhibitors
Therapies for common conditions behind genetic discoveries are all inhibitors mimicking protective loss-of-function variants (prospective review abstract); 36 of 40 discoveries behind approved therapies were for rare conditions. 4
Reported, not yet replicated
Still open here
- A sourced definition of gene module and a worked example.
- What regulators require at this step: not covered.
- How many approved genetics-led drugs began from a noncoding lead variant (supplementary list gated).
Not yet written: Costs, Regulators require, Scenarios.
Sources
- Mountjoy E, Schmidt EM, Carmona M, et al.. An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. Nat Genet (2021). paper; opened 2026-11-17 all records citing this
- Sinnott-Armstrong N, Naqvi S, Rivas M, et al.. GWAS of three molecular traits highlights core genes and pathways alongside a highly polygenic background. Elife (2021). paper; opened 2026-11-17 all records citing this
- Minikel, E., Painter, J., Dong, C., et al.. Refining the impact of genetic evidence on clinical success. Nature (2024). paper; opened 2026-11-17 all records citing this
- Trajanoska, K., et al.. From target discovery to clinical drug development with human genetics. Nature (2023). paper; opened 2026-11-17 all records citing this
- King, E., Davis, J., Degner, J.. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLOS Genetics (2019). paper; opened 2026-11-17 all records citing this
- Lessard S, Chao M, Reis K, et al.. Leveraging large-scale multi-omics evidences to identify therapeutic targets from genome-wide association studies. BMC Genomics (2024). paper; opened 2026-11-17 all records citing this
History of this record (5)
This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Order
- 3
- Stage
- target-id
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/cascade/target-and-gene-module.json